



Design and Synthesis of Novel Tropane Fused Heterocycles of Potential Pharmacological Properties

Thesis Presented by

Fady Noshy Ishak Baseliouis

Bachelor of Pharmaceutical Sciences, Faculty of Pharmacy,
Cairo University, 2009

Research and Development Supervisor
Research and Development Department, Global Napi Pharmaceuticals, 6th
October City, Giza, Egypt
Submitted in partial fulfillment of the

Master Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)
Under supervision of

Dr. Nasser Saad Mohamed

*Professor, Pharmaceutical Chemistry Dept., Faculty of Pharmacy, Ain
Shams University*

Dr. Rabah Ahmed Taha

*Associate Professor, Pharmaceutical Chemistry Dept., Faculty of Pharmacy,
Ain Shams University*

Dr. Riham François George

*Associate Professor, Pharmaceutical Chemistry Dept., Faculty of Pharmacy,
Cairo University*

**Faculty of Pharmacy
Ain Shams University
2017**

Acknowledgement

I would like to thank Professor Dr. Nasser Saad Mohamed, Professor of Pharmaceutical Chemistry, Ain Shams University, Dr. Rabah Ahmed Taha Serya, Associate Professor of Pharmaceutical Chemistry, Ain Shams University and Dr. Riham François George, Associate Professor of Pharmaceutical Chemistry, Cairo University, for their scientific supervision, guidance, support, invaluable assistance and help throughout the whole work. I truly want to express my appreciation for their efforts which allowed this thesis to appear in its final form.

I would like to express my gratefulness to Professor Dr. Adel Girgis, Pesticide Chemistry Department, National Research Centre, for his unlimited help, support, and continuous encouragement. I deeply appreciate his sincere efforts leading to the completion of this thesis in the presented form.

I would like to thank Dr. Peter Mehany, Chairman and Managing Director and Dr. Salwa Gamil, Research and Development Director at Global Napi Pharmaceuticals for facilities allowed.

I want to acknowledge Dr. Mostafa Ahmed Khairy, Research and Development Section Head and all my colleagues at Global Napi Pharmaceuticals for their unconditioned help and support.

CONTENTS

	Page
Acknowledgment	I
List of Figures	V
List of Tables	X
List of Abbreviations	XIII
Abstract	XV
1-Introduction	1
1.1 Definition of Tropane alkaloids.....	1
1.2 Biosynthesis of Tropane alkaloids.....	2
1.3 Naturally occurring tropane derivatives with pharmacological activity	4
1.3.1 Atropine	5
1.3.2 Hyosciamine	7
1.3.3. Scopolamine.....	7
1.3.4 Anisodamine	9
1.3.5 Anisodine	12
1.3.6 Cocaine	13
1.3.7 Pervilleines.....	16
1.4 Tropane ring synthesis	20
1.5 Biological activity of synthetic tropane derivatives	22
1.5.1 Ophthalmology	22
1.5.1.1 Tropeines.....	22
1.5.1.2 Quaternary ammonium salts	23
1.5.2 Gastro intestinal disorders	23
1.5.2.1 Quaternary ammonium salts	23
1.5.2.2 Serotonin receptors antagonists	24

	Page
1.5.3 Bronchodilators and anticholinergics	24
1.5.3.1 Atropine methyl nitrate	24
1.5.3.2 Ipratropium bromide	25
1.5.3.3 Oxitropium bromide.....	25
1.5.3.4 Tiotropium bromide	26
1.5.3.5 Darotropium bromide.....	27
1.5.3.6 Trospium chloride	29
1.5.3.7 Flutropium bromide	30
1.5.3.8 Other anti-muscarinic agents as treatment for COPD	30
1.5.4 Overreactive bladder.....	32
1.5.5 Tropane derivatives with CNS activity.....	32
1.5.6 Local anesthesia.....	39
1.5.7 Anti-migraine.....	41
1.5.8 Anti-HIV	42
1.5.9 Tropane derivatives with anticancer activity	43
2- Rational and design	46
2.1 Chemical design and synthesis	46
2.1.1 Scheme1.....	49
2.1.2 Scheme2.....	49
2.1.3 Scheme3.....	50
2.2 Computational techniques	50
3- Result and Discussion	53
3.1 Chemistry.....	53
3.1.1 8-methyl-8-azabicyclo[3.2.1]octan-3-ones I (10).....	53
3.1.2 Scheme 1.....	53

	Page
3.1.3 Scheme 2.....	52
3.1.4 Scheme 3.....	54
3.2 Single crystal X-ray studies	54
3.3 Biological evaluation	57
3.3.1 Antitumor properties.....	57
3.3.2 Structure activity relationship	59
3.4 Computational chemistry and modeling.....	60
3.4.1 Structure optimization.....	60
3.4.2 2D-QSAR studies	63
3.4.3 ADMET studies	77
4- Conclusions	79
5- Experimental	80
5.1 Chemistry.....	80
5.1.1 Materials and instrumentation	80
5.1.2 Synthesis	81
5.2 Single crystal X-ray studies	109
5.3 Biological Evaluation	109
5.3.1 In vitro antitumor screening.....	109
5.3.2 Data analysis	110
5.4 Computational chemistry and modeling.....	111
5.4.1 Structure optimization.....	111
5.4.2 2D-QSAR studies	112
5.4.3 ADMET studies	113
6- Supplementary materials	114
References.....	153

List of Figures

	Page
Figure 1: Schematic outline of Putrescine Biosynthesis from L-ornithine and arginine.....	2
Figure 2: Schematic outline of Tropinone Biosynthesis from Putrescine.	3
Figure 3: Biotransformation of tropinone to tropine and pseudotropine via action of two distinct tropinone reductase enzyme	4
Figure 4: Schematic representation of tropinone synthetic pathway by Willstätter in 1901.	20
Figure 5: Schematic representation of synthetic pathway of tropinone by Sir Robert Robinson in 1917.	21
Figure 6: An ORTEP view of compound IVa showing the atom-numbering scheme. Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii.	56
Figure 7: A view in projection down the a-axis of the unit cell contents for IVa showing supramolecular assembly parallel to the (1 0 0) plane and H-bonds as dashed lines.	56
Figure 8: A projection of the optimized structure of compound IVa by DFT/B3LYP with 6-31G (d,p) level of theory.....	61

Figure 9: A projection of the optimized structure of compound IVa by semi-empirical AM1.	61
Figure 10: A projection of the optimized structure of compound IVa by semi-empirical PM3.	62
Figure 11: Overlay diagram of IVa; red (X-ray structure), green (AM1), blue (PM3) and yellow (DFT).	63
Figure 12: BMLR-QSAR model plot of correlations representing the observed versus predicted IC_{50} , μM values for the tropane containing-compounds (IIa–f , IVa–i,k–o,q–s and VIa,b) against MCF7 (beast) carcinoma cell line.	64
Figure 13: BMLR-QSAR model plot of correlations representing the observed versus predicted $\log(IC_{50}$, μM) values for the subset group (A+B) against MCF7 (beast) carcinoma cell line.	75
Figure 14: BMLR-QSAR model plot of correlations representing the observed versus predicted $\log(IC_{50}$, μM) values for the subset group (A+C) against MCF7 (beast) carcinoma cell line.	76
Figure 15: BMLR-QSAR model plot of correlations representing the observed versus predicted $\log(IC_{50}$, μM) values for the subset group (B+C) against MCF7 (beast) carcinoma cell line (compound VIa is an outlier).	76
Figure 16: IR spectrum of compound IIIf (KBr pellet).	119
Figure 17: 1H -NMR spectrum of compound IIIf in $CDCl_3$	119

Figure 18: ^{13}C -NMR spectrum of compound II f in CDCl_3	120
Figure 19: IR spectrum of compound IV a (KBr pellet).....	120
Figure 20: ^1H -NMR spectrum of compound IV a in CDCl_3	121
Figure 21: ^1H , ^1H -COSY spectrum of compound IV a in CDCl_3 ...	121
Figure 22: ^{13}C -NMR spectrum of compound IV a in CDCl_3	122
Figure 23: ^1H , ^{13}C -Heteronuclear Single Quantum Coherence (HSQC) spectrum of compound IV a in CDCl_3	122
Figure 24: IR spectrum of compound IV b (KBr pellet).....	123
Figure 25: ^1H -NMR spectrum of compound IV b in CDCl_3	123
Figure 26: ^{13}C -NMR spectrum of compound IV b in CDCl_3	124
Figure 27: IR spectrum of compound IV c (KBr pellet).....	124
Figure 28: ^1H -NMR spectrum of compound IV c in CDCl_3	125
Figure 29: ^{13}C -NMR spectrum of compound IV c in CDCl_3	125
Figure 30: IR spectrum of compound IV d (KBr pellet).....	126
Figure 31: ^1H -NMR spectrum of compound IV d in CDCl_3	126
Figure 32: ^{13}C -NMR spectrum of compound IV d in CDCl_3	127
Figure 33: IR spectrum of compound IV e (KBr pellet).....	127
Figure 34: ^1H -NMR spectrum of compound IV e in CDCl_3	128
Figure 35: ^{13}C -NMR spectrum of compound IV e in CDCl_3	128
Figure 36: IR spectrum of compound IV f (KBr pellet).....	129
Figure 37: ^1H -NMR spectrum of compound IV f in CDCl_3	129
Figure 38: ^{13}C -NMR spectrum of compound IV f in CDCl_3	130
Figure 39: IR spectrum of compound IV g (KBr pellet).....	130
Figure 40: ^1H -NMR spectrum of compound IV g in CDCl_3	131
Figure 41: ^{13}C -NMR spectrum of compound IV g in CDCl_3	131
Figure 42: IR spectrum of compound IV h (KBr pellet).....	132
Figure 43: ^1H -NMR spectrum of compound IV h in CDCl_3	132

Figure 44: ^{13}C -NMR spectrum of compound IVh in CDCl_3	133
Figure 45: IR spectrum of compound IVi (KBr pellet).....	133
Figure 46: ^1H -NMR spectrum of compound IVi in CDCl_3	134
Figure 47: ^{13}C -NMR spectrum of compound IVi in CDCl_3	134
Figure 48: IR spectrum of compound IVj (KBr pellet).....	135
Figure 49: ^1H -NMR spectrum of compound IVj in CDCl_3	135
Figure 50: ^{13}C -NMR spectrum of compound IVj in CDCl_3	136
Figure 51: IR spectrum of compound IVk (KBr pellet).....	136
Figure 52: ^1H -NMR spectrum of compound IVk in CDCl_3	137
Figure 53: ^{13}C -NMR spectrum of compound IVk in CDCl_3	137
Figure 54: IR spectrum of compound IVl (KBr pellet).....	138
Figure 55: ^1H -NMR spectrum of compound IVl in CDCl_3	138
Figure 56: ^{13}C -NMR spectrum of compound IVl in CDCl_3	139
Figure 57: IR spectrum of compound IVm (KBr pellet).....	139
Figure 58: ^1H -NMR spectrum of compound IVm in CDCl_3	140
Figure 59: ^{13}C -NMR spectrum of compound IVm in CDCl_3	140
Figure 60: IR spectrum of compound IVn (KBr pellet).....	141
Figure 61: ^1H -NMR spectrum of compound IVn in CDCl_3	141
Figure 62: ^{13}C -NMR spectrum of compound IVn in CDCl_3	142
Figure 63: IR spectrum of compound IVo (KBr pellet).....	142
Figure 64: ^1H -NMR spectrum of compound IVo in CDCl_3	143
Figure 65: ^{13}C -NMR spectrum of compound IVo in CDCl_3	143
Figure 66: IR spectrum of compound IVp (KBr pellet).....	144
Figure 67: ^1H -NMR spectrum of compound IVp in CDCl_3	144
Figure 68: ^{13}C -NMR spectrum of compound IVp in CDCl_3	145
Figure 69: IR spectrum of compound IVq (KBr pellet).....	145
Figure 70: ^1H -NMR spectrum of compound IVq in CDCl_3	146

Figure 71: ^{13}C -NMR spectrum of compound IVq in CDCl_3	146
Figure 72: IR spectrum of compound IVr (KBr pellet).	147
Figure 73: ^1H -NMR spectrum of compound IVr in CDCl_3	147
Figure 74: ^{13}C -NMR spectrum of compound IVr in CDCl_3	148
Figure 75: IR spectrum of compound IVs (KBr pellet).	148
Figure 76: ^1H -NMR spectrum of compound IVs in CDCl_3	149
Figure 77: ^{13}C -NMR spectrum of compound IVs in CDCl_3	149
Figure 78: IR spectrum of compound VIa (KBr pellet).	150
Figure 79: ^1H -NMR spectrum of compound VIa in CDCl_3	150
Figure 80: ^{13}C -NMR spectrum of compound VIa in CDCl_3	151
Figure 81: ^1H -NMR spectrum of compound VIb in CDCl_3	151
Figure 82: ^1H -NMR spectrum of compound VIb in CDCl_3	152
Figure 83: ^{13}C -NMR spectrum of compound VIb in CDCl_3	152

List of Tables

	Page
Table 1: Hydrogen-bond geometry and non-bonding contacts (Å, °) for Iva	55
Table 2: Antitumor properties of tropane containing-compounds IIa-f , IVa-s , VIa,b and doxorubicin.	58
Table 3: Descriptor of the BMLR-QSAR model for the antitumor tropane containing-compounds (IIa-f , IVa-i,k-o,q-s and VIa,b) against MCF7 (beast) carcinoma cell line.	65
Table 4: Observed and estimated/predicted activity values for the antitumor tropane containing-compounds (IIa-f , IVa-i,k-o,q-s and VIa,b) according to the BMLR-QSAR model due to MCF7 (breast) carcinoma cell line.	68
Table 5: Descriptor of the BMLR-QSAR model for the subset group (A+B) against MCF7 (beast) carcinoma cell line.	69
Table 6: Observed and estimated/predicted activity values for the subset group (A+B) antitumor active agents according to the (A+B)-QSAR model due to MCF7 (breast) carcinoma cell line.	70
Table 7: Observed and estimated/predicted activity values for the subset group (C, as an external test set) according to the (A+B)-QSAR model due to MCF7 (breast) carcinoma cell line.	71
Table 8: Descriptor of the BMLR-QSAR model for the subset group (A+C) against MCF7 (beast) carcinoma cell line.	71

	Page
Table 9: Observed and estimated/predicted activity values for the subset group (A+C) antitumor active agents according to the (A+C)-QSAR model due to MCF7 (breast) carcinoma cell line.	72
Table 10: Observed and estimated/predicted activity values for the subset group (B, as an external test set) according to the (A+C)-QSAR model due to MCF7 (breast) carcinoma cell line.....	73
Table 11: Descriptor of the BMLR-QSAR model for the subset group (B+C) against MCF7 (beast) carcinoma cell line.	73
Table 12: Observed and estimated/predicted activity values for the subset group (B+C) antitumor active agents according to the (B+C)-QSAR model due to MCF7 (breast) carcinoma cell line.	74
Table 13: Observed and estimated/predicted activity values for the subset group (A, as an external test set) according to the (B+C)-QSAR model due to MCF7 (breast) carcinoma cell line.....	75
Table 14: ADMET descriptor values for the antitumor active agents against MCF7 cell line.	78
Table 15: Experimental and optimized intramolecular geometrical parameters (bond lengths, Å) of compound IVa	114
Table 16: Experimental and optimized intramolecular geometrical parameters (bond angles, °) of compound IVa	115

	Page
Table 17: Molecular descriptor values of the BMLR-QSAR model for the antitumor tropane containing-compounds (IIa–f , IVa–i,k–o,q–s and VIa,b) according to the BMLR-QSAR model due to MCF7 (breast) carcinoma cell line.....	117
Table 18: Crystal data and structure refinement parameters of compound IVa	118

List of Abbreviations

2D-QSAR:	Two Dimensional Quantitative Structure Activity Relationship.
5HT₃:	Serotonin Type 3 Receptor.
α7nAChR :	α 7 Nicotinic Acetylcholine Receptor.
ADC:	Arginine Decarboxylase.
ADMET:	Absorption, Distribution, Metabolism, Excretion, Toxicity.
AGDI:	Agmatine Deiminase.
BMLR:	Best Multi-Linear Regression.
CCR5:	C-C Chemokine Receptor Type 5.
CNS:	Central Nervous System.
DFT:	Density Functional Theory.
FLIPR:	Fluorometric Image Plate Reader.
H6H:	Hyoscyamine 6 β -hydroxylase.
HSP90:	Heat Shock Protein 90.
NADPH:	Dihyronicotinamide-Adenine Dinucleotide Phosphate.
ODC:	Ornithine Decarboxylase.
PEA:	Pulseless Electrical Activity.
PMT:	Putrescine Methyl Transferase.
QSAR:	Quantitative Structure Activity Relationship.
R²:	Squared Correlation Coefficient
R²cvMO:	Squared Cross-Validation “leave many-out, LMO” coefficient
R²cvOO:	Squared Cross-Validation “leave one-out, LOO” coefficient.
RAID:	Rapid Access to Invention Development.

REM:	Rapid Eye Movement.
SAR:	Structure Activity Relationship.
TLC:	Thin Layer Chromatography.
TR-I:	Tropinone Reductase I.
TR-II:	Tropinone Reductase II.
UPLIFT:	Understanding Potential Long-Term Impacts on Function with Tiotropium.